Analysts Set iRadimed Corporation (NASDAQ:IRMD) Price Target at $87.33

Shares of iRadimed Corporation (NASDAQ:IRMD) have been assigned an average rating of “Moderate Buy” from the four ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $95.00.

Several research firms recently commented on IRMD. Roth Mkm set a $90.00 price objective on iRadimed in a research note on Friday, October 31st. Zacks Research upgraded iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Lake Street Capital reaffirmed a “buy” rating and set a $100.00 price target on shares of iRadimed in a research report on Monday, November 3rd. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Finally, Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th.

Insider Buying and Selling

In other news, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $101.84, for a total value of $509,200.00. Following the completion of the transaction, the chief executive officer directly owned 2,267,500 shares of the company’s stock, valued at $230,922,200. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO John Glenn sold 15,000 shares of iRadimed stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the transaction, the chief financial officer owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 60,000 shares of company stock worth $5,586,300 over the last 90 days. 36.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Johnson Investment Counsel Inc. lifted its stake in iRadimed by 0.7% in the third quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock worth $1,839,000 after purchasing an additional 187 shares during the last quarter. Summit Global Investments increased its holdings in shares of iRadimed by 2.7% in the third quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock worth $508,000 after buying an additional 188 shares during the period. CWM LLC lifted its stake in shares of iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 234 shares during the period. Finally, Farther Finance Advisors LLC grew its position in iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 397 shares during the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Stock Performance

NASDAQ:IRMD opened at $100.86 on Tuesday. iRadimed has a 52 week low of $47.48 and a 52 week high of $104.93. The firm has a 50-day moving average price of $96.15 and a two-hundred day moving average price of $79.84. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of 61.13 and a beta of 1.09.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. The company had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, sell-side analysts forecast that iRadimed will post 1.66 earnings per share for the current year.

iRadimed Dividend Announcement

The firm also recently declared a special dividend, which was paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th were given a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s payout ratio is 41.21%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.